Lipitor

Atorvastatin, the active ingredient in Lipitor, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adults. GNH USA supplies Lipitor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on cholesterol metabolism and is indicated for several lipid‑related conditions. - Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol. - Mixed dyslipidemia: reduces triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Primary and secondary prevention of cardiovascular disease: decreases the risk of myocardial infarction, stroke and related events. - Familial hypercholesterolemia: helps manage genetically elevated cholesterol levels.

Common side effects are generally mild and reversible.

Common Side Effects: - Muscle pain or weakness - Elevated liver enzymes - Headache - Nausea or abdominal discomfort - Dizziness - Fatigue

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown) - Acute liver injury - Severe allergic reactions (e.g., rash, angioedema) - Myopathy with marked creatine kinase elevation - Hepatic failure - Life‑threatening hypersensitivity reactions

Patients should be monitored for safety and drug interactions before and during therapy. - Liver function monitoring: obtain baseline and periodic liver‑function tests. - Muscle symptom monitoring: advise patients to report unexplained muscle pain, tenderness or weakness. - Pregnancy contraindication: avoid use in pregnancy (Category X). - Drug interaction review: assess concomitant use of CYP3A4 inhibitors and other lipid‑lowering agents. - Renal impairment dosing: consider dose adjustment in severe renal dysfunction. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Atorvastatin may interact with several medicines that affect its metabolism or increase the risk of muscle toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole) - Grapefruit juice - Cyclosporine

Moderate Interactions (Monitor Closely): - Bile‑acid sequestrants (may reduce absorption) - Warfarin (potential for altered anticoagulant effect) - Fibrates (increased risk of myopathy)